NO20064012L - Kjemisk prosess - Google Patents

Kjemisk prosess

Info

Publication number
NO20064012L
NO20064012L NO20064012A NO20064012A NO20064012L NO 20064012 L NO20064012 L NO 20064012L NO 20064012 A NO20064012 A NO 20064012A NO 20064012 A NO20064012 A NO 20064012A NO 20064012 L NO20064012 L NO 20064012L
Authority
NO
Norway
Prior art keywords
chemical process
formulas
compounds
preparation
chemical
Prior art date
Application number
NO20064012A
Other languages
English (en)
Inventor
John Roger Butlin
Philip John Hogan
Margaret Anne Butlin
Andreas Meudt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20064012L publication Critical patent/NO20064012L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Fremgangsmåte for fremstilling av forbindelser med formel I og IV er beskrevet.
NO20064012A 2004-02-20 2006-09-06 Kjemisk prosess NO20064012L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0403744.6A GB0403744D0 (en) 2004-02-20 2004-02-20 Chemical process
PCT/GB2005/000567 WO2005080403A2 (en) 2004-02-20 2005-02-17 Chemical process

Publications (1)

Publication Number Publication Date
NO20064012L true NO20064012L (no) 2006-11-06

Family

ID=32040047

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064012A NO20064012L (no) 2004-02-20 2006-09-06 Kjemisk prosess

Country Status (32)

Country Link
US (2) US7626020B2 (no)
EP (3) EP1718655A2 (no)
JP (2) JP2007523906A (no)
KR (2) KR20120036998A (no)
CN (1) CN1922193B (no)
AR (1) AR047810A1 (no)
AT (1) ATE535532T1 (no)
AU (1) AU2005214138B2 (no)
BR (1) BRPI0507847A (no)
CA (1) CA2555554A1 (no)
CL (1) CL2011003138A1 (no)
CY (1) CY1112555T1 (no)
DK (1) DK2135873T3 (no)
ES (1) ES2375201T3 (no)
GB (1) GB0403744D0 (no)
HK (1) HK1139689A1 (no)
HR (1) HRP20120031T1 (no)
IL (2) IL177505A (no)
MY (1) MY142268A (no)
NO (1) NO20064012L (no)
PL (1) PL2135873T3 (no)
PT (1) PT2135873E (no)
RS (1) RS52300B (no)
RU (1) RU2386636C2 (no)
SA (1) SA05260017B1 (no)
SG (1) SG153856A1 (no)
SI (1) SI2135873T1 (no)
TW (1) TWI347947B (no)
UA (1) UA83418C2 (no)
UY (1) UY28754A1 (no)
WO (1) WO2005080403A2 (no)
ZA (1) ZA200606579B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
CA2667545A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
ES2493916T3 (es) 2009-04-07 2014-09-12 Infinity Pharmaceuticals, Inc. Inhibidores de hidrolasa de amida de ácidos grasos
EP2417115A4 (en) 2009-04-07 2012-10-31 Infinity Pharmaceuticals Inc FATTY ACID AMIDE HYDROLASE INHIBITORS
JP2013518886A (ja) 2010-02-03 2013-05-23 インフイニトイ プハルマセウトイカルス インコーポレイテッド 脂肪酸アミドヒドロラーゼ阻害剤
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法
EP3362462B1 (en) 2015-10-12 2021-07-21 Advanced Cell Diagnostics, Inc. In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (no) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (no) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
AU3011299A (en) 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
NZ508154A (en) 1998-04-29 2003-07-25 Osi Pharm Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
US6355678B1 (en) 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
PT1121111E (pt) 1998-10-15 2010-05-17 Imp Innovations Ltd Compostos para o tratamento de perda de peso
DE19857765A1 (de) 1998-12-15 2000-06-21 Clariant Gmbh Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
WO2001044239A2 (en) 1999-12-15 2001-06-21 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
AR031679A1 (es) 2000-02-16 2003-10-01 Astellas Pharma Inc Una composicion farmaceutica
MXPA02010764A (es) 2000-05-31 2003-03-10 Warner Lambert Co Combinaciones de un antagonista del receptor endotelina y un compuesto antiepileptico que tiene propiedades para aliviar el dolor o analgesico.
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE10059418A1 (de) * 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
AU2002241736A1 (en) 2000-12-21 2002-07-01 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
JP2005504721A (ja) 2001-03-06 2005-02-17 セレジィ ファーマシューティカルス， インコーポレイテッド 尿生殖障害の処置のための化合物および方法
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
IL158071A0 (en) 2001-04-11 2004-03-28 Abbott Lab Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
JP2005504040A (ja) * 2001-08-03 2005-02-10 スミスクライン ビーチャム コーポレーション カテプシンＫ阻害剤としてのα−ケトアミド誘導体
WO2003015820A1 (fr) 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7868172B2 (en) 2003-12-20 2011-01-11 Merck Patent Gmbh 2-(hetero)-aryl substituted tetrahydroquinoline derivatives
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
SG153856A1 (en) 2009-07-29
BRPI0507847A (pt) 2007-07-10
ATE535532T1 (de) 2011-12-15
AU2005214138B2 (en) 2009-02-12
IL177505A0 (en) 2006-12-10
EP2135873A3 (en) 2010-03-24
EP2135873A2 (en) 2009-12-23
HK1139689A1 (en) 2010-09-24
WO2005080403A3 (en) 2005-11-24
US7626020B2 (en) 2009-12-01
KR20060129483A (ko) 2006-12-15
RS52300B (en) 2012-12-31
AU2005214138A1 (en) 2005-09-01
EP2325189A3 (en) 2011-10-26
ES2375201T3 (es) 2012-02-27
IL194709A (en) 2010-12-30
WO2005080403A2 (en) 2005-09-01
CN1922193A (zh) 2007-02-28
KR20120036998A (ko) 2012-04-18
CY1112555T1 (el) 2016-02-10
MY142268A (en) 2010-11-15
TWI347947B (en) 2011-09-01
UA83418C2 (uk) 2008-07-10
TW200538451A (en) 2005-12-01
RU2006133455A (ru) 2008-03-27
SI2135873T1 (sl) 2012-03-30
PL2135873T3 (pl) 2012-03-30
ZA200606579B (en) 2008-01-30
EP2135873B1 (en) 2011-11-30
SA05260017B1 (ar) 2008-07-14
KR101196111B1 (ko) 2012-10-30
PT2135873E (pt) 2012-01-16
RU2386636C2 (ru) 2010-04-20
CN1922193B (zh) 2012-12-26
US20100094010A1 (en) 2010-04-15
JP2007523906A (ja) 2007-08-23
HRP20120031T1 (hr) 2012-02-29
GB0403744D0 (en) 2004-03-24
UY28754A1 (es) 2005-09-30
EP1718655A2 (en) 2006-11-08
US20080161565A1 (en) 2008-07-03
CL2011003138A1 (es) 2012-06-22
AR047810A1 (es) 2006-02-22
IL177505A (en) 2010-12-30
JP2012031174A (ja) 2012-02-16
CA2555554A1 (en) 2005-09-01
EP2325189A2 (en) 2011-05-25
DK2135873T3 (da) 2012-02-13

Similar Documents

Publication Publication Date Title
NO20064012L (no) Kjemisk prosess
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
NO20066055L (no) Pyridinderivater
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20060044L (no) Fremgangsmate for fremstilling av substituerte 3-aryl-butyl-aminforbindelser
NO20050065L (no) Kjemiske forbindelser
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
DE602004030334D1 (de) Synthese von 5-substituierten 7-azaindolen und 7-azaindolinen
NO20072872L (no) Kjemisk prosess
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
SG156689A1 (en) Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
NO20055741D0 (no) Nye kjemiske forbindelser
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
NO20071574L (no) Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander.
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
NO20064632L (no) Tricykliske imidazopyridiner
NO20055750L (no) Nye kjemiske forbindelser
NO20063220L (no) Tricykliske imidazopyridiner for anvendelse som gastriske sekresjonsinhibitorer
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application